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Essentials
• Procedural interruption of anticoagulation is associated with thrombotic and bleeding complications.
• We compared postoperative complication rates following interruption of vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs).
• The interruption of VKAs was associated with more postoperative major bleeding as compared to DOACs.
• Close follow-up is warranted when reinitiating VKA anticoagulation postoperatively.
| INTRODUC TI ON
Atrial fibrillation (AF) is a common disorder that is estimated to affect up to 5.6 million patients in the United States by the year 2050. 1 Both the direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) are used for stroke prevention in AF. It has been estimated that up to 10% of patients on therapeutic anticoagulation undergo periprocedural interruption of their anticoagulation each year. 2 Temporary interruption of anticoagulation can be associated with significant morbidity and mortality in the form of thromboembolic and bleeding complications. Real-world studies have consistently shown higher-than-expected postoperative thromboembolic event rates as compared to predicted rates using prorated calculations, 2,3 which involve estimating annual stroke risk using the CHADS 2 score, and dividing the value by 365 to obtain an estimated daily risk of stroke. Calculations used to estimate the perioperative stroke risk rely on risk stratification tools that were derived from trial populations, 4, 5 which may underestimate the underlying risk of stroke. With regard to bleeding, randomized controlled trials (RCTs), 6 post hoc analyses of RCT data, [7] [8] [9] [10] and large prospective cohort studies 11 have found that major bleeding rates within 30 days of perioperative anticoagulation interruption range from 0.6% to 3% for patients on DOACs 11, 12 and from 1% to 8% for patients on VKAs. 13 These postoperative 30-day rates are higher than would be expected based on annual rates of major bleeding. [14] [15] [16] [17] [18] Patients receiving perioperative bridging low-molecular-weight heparin (LMWH) have been shown to be at particularly high risk of postoperative bleeding. 13, 19, 20 Direct oral anticoagulants have a short half-life and a fast onset of action, both of which confer an ideal pharmacokinetic profile for perioperative use. 21 Warfarin, due to its long half-life, must be interrupted for several days prior to procedures. It has a slow onset of action of several days. 22 Thus, patients are often subtherapeutic for 4 to 8 days surrounding the time of the procedure, and physicians may opt to use bridging LMWH in patients at high risk of thrombotic complications.
Despite important differences in perioperative management
and pharmacokinetics between DOACs and VKAs, there is a paucity of data comparing perioperative outcomes between DOACand VKA-treated patients. We sought to compare postoperative event rates following the perioperative interruption of VKAs and DOACs, using defined perioperative anticoagulation management protocols.
| METHODS

| Study population
We undertook a single-center, retrospective cohort study that com- Patients who underwent a second planned elective procedure during their 30-day follow-up period were included to maintain external validity of the study. Data were extracted using a standardized electronic data extraction form and stored in an electronic database.
The CHADS 2 score was recorded in this study over the CHA 2 DS 2 -Vasc score, given it is more commonly used at our institution and was more frequently recorded on chart documentation. This study was approved by the Ottawa Health Science Network Research Ethics Board.
| Perioperative anticoagulation management
Perioperative VKA interruption was done as suggested by clinical practice guidelines. 22 VKAs were discontinued 5 days prior to the procedure, and resumed on the day of the procedure, provided adequate hemostasis was achieved and neuraxial anesthesia had been discontinued. Patients undergoing high-bleeding-risk procedures generally have an International Normalized Ratio (INR) checked on preoperative day 1, and if their INR is >1.5, they receive vitamin K orally. 23 Patients received a loading dose of VKA (double patient's home dose) on postoperative days (PODs) 0 and 1, followed by an INR measurement on POD 2, with subsequent VKA dosing based on the INR result. Perioperative bridging with LMWH was used only for patients with CHADS 2 scores of 5 to 6 or in patients with stroke within the past 6 months. Perioperative interruption of DOACs was done as suggested by Thrombosis Canada guidelines, 24 with anticoagulation held for 3 half-lives prior to standard bleeding risk procedures and 5 half-lives for high-bleeding-risk procedures. DOACs were resumed approximately 24 hours following standard bleeding risk procedures, and approximately 48 to 72 hours following high-bleeding-risk procedures, provided adequate hemostasis was achieved and neuraxial anesthesia had been discontinued. These DOAC perioperative interruption practices are consistent with the protocol used in the PAUSE (Perioperative Anticoagulant Use for Surgery Evaluation) trial. 11 If postoperative delays in the resumption of DOACs occurred due to neuraxial anesthesia or ileus, prophylactic doses of LMWH were used until the DOAC could be resumed. Although physicians at our institution usually adhere to the above perioperative interruption protocols, decisions surrounding perioperative anticoagulation management are ultimately left to the discretion of the treating physician if clinical factors require deviation from the above guidelines, as would be the case at most health care institutions. Procedural bleeding risk was determined based on a modified version of a previously published risk-stratification scheme (Table S1 ). 25 Our risk stratification scheme is consistent with published ISTH guidance. 26 All pacemaker/implantable cardioverter-defibrillator insertions were considered "standard" bleeding risk procedures based on the results of BRUISE CONTROL (Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial) and BRUISE CONTROL-2. 27, 28 All colonoscopies were considered "high" bleeding risk given that it was often unknown at the time of periprocedural planning whether a polypectomy would be performed (ie, screening colonoscopies).
All procedures involving neuraxial anesthesia are considered "high" bleeding risk at our institution. were defined according to ISTH definitions. [29] [30] [31] Outcome events were independently adjudicated by 2 investigators (GLG and MC).
| Study outcomes
| Statistical analysis
We compared patient demographics between DOACs and VKAs on a per-patient basis. Dichotomous data are presented as numbers and percentages, while continuous data are expressed as means and standard deviations. P values were calculated using independent t-Test, chi-square/Fisher's exact test where appropriate. Outcome data analysis was done on a per-interruption basis. All procedural interruptions were included, accounting for random effects, as a patient might have had >1 procedural interruption. We used multivariable mixed-effects logistic-regression models adjusting for possible independent confounding variables, including age, CHADS 2 , renal function, inpatient/outpatient status, and random effects to compare outcomes between DOACs and VKAs. Data were analyzed with the use of SAS software, version 9.4 (SAS Institute, Cary, NC, USA).
| RESULTS
| Study population
Of 1330 patients screened for study eligibility, a total of 524 patients undergoing 572 perioperative interruptions met inclusion criteria and were included in the analysis ( Figure S1 ). Table 1 . A total of 325 DOAC patients and 199 VKA patients underwent 351 and 221 periprocedural interruptions, respectively (Table 1) . VKA patients had a significantly higher mean age and CHADS 2 score. A greater proportion of VKA patients had evidence of renal dysfunction, as evidenced by a creatinine clearance of <60 mL/min. Mean HAS-BLED score was 2.2 ± 0.9 and 2.4 ± 0.9 for DOAC and VKA patients, respectively (P = .10).
Baseline characteristics of included patients are depicted in
| Procedures
DOAC patients underwent standard and high-bleeding-risk procedures in 44.7% and 55.3% of cases, respectively ( Table 2 ). VKA patients underwent standard and high-bleeding-risk procedures in 47.1% and 52.9% of cases, respectively. Patients on DOAC anticoagulation were more likely to have undergone inpatient procedures, whereas patients on VKA anticoagulation were more likely to have undergone plastic surgery. 
| Perioperative anticoagulation
| Study outcomes
There were a total of 2 postoperative ATEs, both in patients on a DOAC, yielding a 30-day postoperative ATE rate of 0.57% (95% confidence interval [CI], 0.27-0.87) for the DOAC cohort ( Table 4 ). The first event was a CVA that occurred on POD 22 in a patient on apixaban with a CHADS 2 score of 5, and the second event was a popliteal artery thromboembolism that occurred on POD 4 in a patient on dabigatran with a CHADS 2 score of 1. Both patients resumed their home DOAC dosing within 36 hours postoperatively. There were no ATEs in the VKA cohort.
There were a total of 2 major bleeding events in the DOAC cohort over a 30-day postoperative follow-up period (0.57%; 95% CI, 0.27-0.87), whereas 8 major bleeding events occurred in the VKA cohort (3.62%; 95% CI, 0.0-7.3). There were significantly more postoperative major bleeding events in the VKA cohort as compared to the DOAC cohort (P = 0.0178). This result remained statistically significant after adjustments for age, CHADS 2 score, renal function, and inpatient procedure status between the 2 cohorts (P = 0.0232). An overview of each major bleeding event is provided in 
| D ISCUSS I ON
Our study assessed postoperative thromboembolic and bleeding complications following perioperative interruption of DOACs and VKAs using a contemporary perioperative interruption protocol.
Postoperative major bleeding rates at 30 days were higher in patients on VKAs.
Previous analyses 7-10 have retrospectively assessed postoperative outcomes following anticoagulation interruptions using data from the 4 prospective randomized controlled trials evaluating the efficacy and safety of DOACs in AF. [32] [33] [34] [35] These results were pooled in a meta-analysis, 12 and no differences in postoperative major bleeding or ATEs were detected when comparing DOACs to VKAs.
However, these studies excluded patients with planned major procedures at study entry, which may have led to selection bias. 32, 34, 36 Perioperative anticoagulation instructions provided to local investigators left decisions surrounding bridging anticoagulation and anticoagulation resumption to the treating physician. Bridging 
TA B L E 2 Procedural characteristics
anticoagulation was used for patients on DOACs in these studies, and the LMWH dosing (prophylactic vs. therapeutic) used for bridging is unknown. 7-10 Moreover, procedural bleeding risk stratification was not incorporated into periprocedural anticoagulation management protocols in 2 of these studies. [34] [35] [36] Thus, the perioperative management of anticoagulation in our VKA and DOAC cohorts may be more reflective of current practice standards.
Patients in both our VKA and DOAC cohorts underwent a wide range of different procedures, and more than half of these procedures were classified as high bleeding risk for patients on both DOACs and VKAs. There was no significant difference in procedural bleeding risk between the VKA and DOAC cohorts, and most procedural subtypes were evenly distributed between the 2 cohorts ( We did find a higher postoperative rate of major bleeding among patients on VKAs. The reasons for this finding could be severalfold. -48  -36  -24  -12  0  12  24  36  48  60  72  84  96  108  120  132  144  156  168  180  192  204  216  228  240  252  264  276  288  300  312  324  336  348  360  372  384  396  408  420  432  444  456  468  480  492  504  516  528  540  552  576  564  588  600  612  624  636  648  660 Our study has several other limitations. This was a retrospective chart review, and thus, our results are only as accurate as the data recorded in our electronic medical record. We cannot rule out the presence of missing data and resultant information bias. Second, although we did try to adjust for all variables that were likely to have an impact on postprocedural bleeding rates, we cannot rule out the possibility of residual confounding as a contributor to the difference observed between our 2 study arms. Third, although patients will often return to the same hospital at which they had their surgery, we cannot rule out the possibility of missed events based on presentation to alternative peripheral hospitals that would not have been captured in our medical records. We attempted to mitigate this bias by reviewing province-wide bloodwork results and reviewing appro- 
